Tesaro’s PARP ovarian cancer drug (niraparib) hits PhIII goal; prepares to file

financial biotech news

 The Waltham, MA-based biotech said its Phase III trial for niraparib hit its primary endpoint of progression-free survival (PFS) against placebo across several sets of patients--including those who were positive for germline BRCA mutation, and another set that do not carry this mutation--as well as those who have homologous recombination deficient (HRD) tumors as determined by a diagnostic kit.